Secondary Malignancies Following CAR T‐Cell Therapy for B‐Cell Malignancies: A Retrospective Analysis

Introduction: Chimeric antigen receptor T-cell (CART) therapy has shown clinical efficacy in relapsed and refractory large B-cell malignancies. There is emerging data on the long-term complications including risk of secondary malignancies. We aimed to describe the incidence and characteristics of secondary malignancies following CART therapy. Methods: We performed a single-center retrospective analysis of a prospectively collected cohort of 87 …